Clinical Research Focus. 38th Edition

Discrepancies in AI Clinical Trial Reporting: A Call for Transparency

A new eClinicalMedicine study highlights inconsistencies between AI clinical trial results reported in registries and published in journals. Selective reporting of secondary outcomes and adverse events raises concerns about evidence reliability. Researchers emphasize the need for stricter adherence to reporting guidelines to improve transparency in AI-driven healthcare.

Please follow the link to learn more.

World Cancer Day 2025: How Clinical Trials Are Shaping the Future of Cancer Treatment

On World Cancer Day, we reflect on the progress made in the fight against cancer and the challenges ahead. With over 2 million new cases diagnosed in the US in 2024 alone, cancer remains a leading cause of death. However, breakthroughs in early detection, targeted therapies, and clinical trial innovations are reshaping oncology care. Clinical trials drive these advancements, with 28,909 ongoing oncology studies worldwide exploring novel treatments across various cancer types.

Please follow the link to learn more.

Key Takeaways from SCOPE 2025: Insights from Cromos Pharma’s US Business Development Director

With the conclusion of the 16th Annual Summit for Clinical Operations Executives (SCOPE) held from February 3-6, 2025, in Orlando, industry experts shared key insights into the future of clinical research and development. Among those gaining firsthand insights into these industry trends was Nicole Brenna, US Business Development Director at Cromos Pharma, who attended SCOPE 2025 and compiled the key takeaways presented in this report.

Please follow the link to learn more.

FDA Approves a Novel Non-Opioid Treatment for Acute Pain

The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic for moderate to severe acute pain. It blocks sodium channels to prevent pain signals from reaching the brain. Clinical trials showed significant pain reduction, offering a new alternative to opioids.

Please follow the link to learn more.

Regulatory Pathways for Rare Disease Drug Development: What Sponsors Need to Know – Rare Disease Day Special

On Rare Disease Day, we emphasize the critical need for ongoing research and innovation in rare disease treatments. With over 440 million people worldwide affected, the call for stronger advocacy and action has never been more urgent. In this article, we explore the key regulatory programs available in the US and Europe and how sponsors can leverage them to optimize timelines and costs.

Please follow the link to learn more.

Dental Flossing Linked to Reduced Ischemic Stroke Risk

A recent study published in Stroke suggests that individuals who regularly floss their teeth may have a lower risk of developing ischemic strokes, particularly those caused by cardioembolic events and associated with atrial fibrillation. The findings highlight the potential importance of oral hygiene in stroke prevention.

Please follow the link to learn more.

Severe Infections May Increase Heart Failure Risk, NIH Study Finds

A new NIH-funded study reveals that adults hospitalized for severe infections, such as sepsis or respiratory infections, are over twice as likely to develop heart failure years later. The findings highlight the importance of infection prevention and personalized cardiovascular care.

Please follow the link to learn more.

Fixed-Duration Acalabrutinib Regimen Extends Survival in Chronic Lymphocytic Leukemia

A phase 3 trial shows that fixed-duration acalabrutinib–venetoclax, with or without obinutuzumab, significantly improves progression-free survival in patients with previously untreated chronic lymphocytic leukemia (CLL) compared to chemoimmunotherapy. The findings suggest a shift toward time-limited, targeted therapies in CLL treatment.

Please follow the link to learn more.

Roche Introduces Breakthrough SBX Technology for Faster Genome Sequencing

Roche’s Sequencing by Expansion (SBX) technology slashes genome sequencing time from days to hours, enabling faster research and clinical breakthroughs in cancer, immune disorders, and neurodegenerative diseases.

Bulgaria: A Rising Hub for Clinical Research in Europe

Bulgaria is quickly becoming a key hub for clinical research in Europe, thanks to its strong regulatory framework, skilled professionals, and cost-effective environment. With a growing number of clinical trials and streamlined approval processes, the country offers significant advantages for sponsors and CROs.

Please follow the link to learn more.